Back to results

Publikationsserver der RWTH Aachen University

Pilot-scale process development for the purification of the recombinant antibody 2G12 from transgenic tobacco

Abstract

dc:description

The production of recombinant therapeutic proteins is becoming increasingly important as demand rises and the industry reaches its production capacity. Transgenic plants offer an alternative production system to the established platforms, but this requires the development of downstream processing schemes tailored for both the platform and the product. The aim of this thesis, within the EU-funded project Pharma-Planta, was to develop and optimize downstream processing strategies for the purification of the recombinant anti-HIV antibody 2G12. Different techniques were successfully combined into a process strategy to fulfill this objective. Clinical-grade recombinant antibody was purified using by the following process steps and industrially available equipment: manual harvest, dispersion and extraction, pH shift in the crude extract, fiber removal by filtration, clarification by filtration, capture by affinity Protein A membrane chromatography, intermediate purification by ceramic hydroxyapatite chromatography, polishing by virus filtration, concentration by ultrafiltration, diafiltration by ultrafiltration, final concentration and formulation. The process recovery of 60% resulted in a final yield of 3.7 g of clinical-grade tobacco-derived antibody purified from 216 kg leaf material, equal to 880 l crude extract. The antibody was polished to a purity >99%, consisting of 99.9% monomeric Ab with an in vitro binding activity of 93% and an in vitro neutralizing activity of 103% relative to the CHO2G12. This thesis established the basis for reproducible and predictable processing of plant material at the hundred-kilogram scale, and shows how further upscaling could be achieved.

Degree

thesis:*
Grantor dc:publisher
Publikationsserver der RWTH Aachen University
Year dc:date
2009

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Lobedann, Martin
Contributors dc:contributor
  • Fischer, Rainer

Subjects

dc:subject × 22

Rights

dc:rights
Statement dc:rights
  • info:eu-repo/semantics/openAccess
Language dc:language
eng

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
RWTH Aachen University
Base URL
publications.rwth-aachen.de/oai2d
Last updated
2026-07-30
Source record
OAI-PMH GetRecord
citation

Lobedann, Martin. Pilot-scale process development for the purification of the recombinant antibody 2G12 from transgenic tobacco. Publikationsserver der RWTH Aachen University, 2009. https://publications.rwth-aachen.de/record/51729